Nielsen M S, Nykjaer A, Warshawsky I, Schwartz A L, Gliemann J
Department of Medical Biochemistry, University of Aarhus, Denmark.
J Biol Chem. 1995 Oct 6;270(40):23713-9. doi: 10.1074/jbc.270.40.23713.
The endocytic alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein (alpha 2MR/LRP) binds several classes of extracellular ligands at independent sites. In addition, alpha 2MR/LRP can bind multiple copies of the 39-40-kDa receptor-associated protein (RAP). Both amino-terminal and carboxyl-terminal fragments of RAP exhibit affinity, and the fragments apparently bind to different sites on the receptor. RAP completely inhibits the binding of all presently known extracellular ligands, whereas several ligands such as alpha 2-macroglobulin and tissue-type plasminogen activator are poor inhibitors of RAP binding. Since RAP is largely an intracellular molecule that normally does not occupy alpha 2MR/LRP at the cell surface, we hypothesized that an established extracellular ligand might bind to those sites on the receptor capable of binding the RAP fragments. We found complete cross-competition between carboxyl-terminal RAP fragments and fragments of lipoprotein lipase containing the recently identified binding domain for alpha 2MR/LRP (Nykjaer, A., Nielsen, M., Lookene, A., Meyer, N., Røigaard, H., Etzerodt, M., Beisiegel, U., Olivecrona, G., and Gliemann, J. (1994) J. Biol. Chem. 269, 31747-31755). Moreover, the lipoprotein lipase fragment completely inhibited the binding of several alpha 2MR/LRP ligands in a pattern similar to that of carboxyl-terminal RAP fragments. On the other hand, the amino-terminal RAP fragment was a poor competitor of binding of the lipoprotein lipase fragment, whereas it competed effectively with pro-uPA for binding to the receptor. The results provide evidence that lipoprotein lipase binds to the site on alpha2MR/LRP also available for binding of the carboxyl-terminal domain of RAP and suggest that pro-uPA may bind to or overlap the site available for the amino-terminal domain of RAP.
内吞性α2-巨球蛋白受体/低密度脂蛋白受体相关蛋白(α2MR/LRP)在独立位点结合几类细胞外配体。此外,α2MR/LRP能结合多个拷贝的39 - 40 kDa受体相关蛋白(RAP)。RAP的氨基末端和羧基末端片段均表现出亲和力,且这些片段显然结合于受体上不同的位点。RAP完全抑制所有目前已知的细胞外配体的结合,而几种配体如α2-巨球蛋白和组织型纤溶酶原激活剂对RAP结合的抑制作用较弱。由于RAP主要是一种细胞内分子,通常不在细胞表面占据α2MR/LRP,我们推测一种已确定的细胞外配体可能结合于受体上能够结合RAP片段的那些位点。我们发现羧基末端RAP片段与含有最近确定的α2MR/LRP结合结构域的脂蛋白脂肪酶片段之间存在完全交叉竞争(尼克亚尔,A.,尼尔森,M.,洛克内,A.,迈耶,N.,勒伊高尔德,H.,埃策罗德特,M.,贝西格尔,U.,奥利克罗纳,G.,和格利曼,J.(1994年)《生物化学杂志》269,31747 - 31755)。此外,脂蛋白脂肪酶片段以与羧基末端RAP片段相似的模式完全抑制几种α2MR/LRP配体的结合。另一方面,氨基末端RAP片段对脂蛋白脂肪酶片段结合的竞争作用较弱,而它能有效地与pro-uPA竞争结合受体。这些结果提供了证据,表明脂蛋白脂肪酶结合于α2MR/LRP上也可用于结合RAP羧基末端结构域的位点,并提示pro-uPA可能结合于或与可用于RAP氨基末端结构域的位点重叠。